J&J ramps up its bladder cancer battle
The first approval for TAR-200 is on the horizon, setting up a challenge to Keytruda.
The month ahead: October’s upcoming events
Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.
Gritstone has a mountain to climb with Granite
The group is persevering with Granite, but funds might be hard to come by.
